These benefits, along with a earlier report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,two support the thought of targeting ACKR3 as a novel strategy to modulate the opioid process, which could open up new therapeutic avenues for opioid-associated disorders. January 3, 2024 Donating is https://deannojcs.wssblogs.com/26812589/the-conolidine-diaries